Valuation: Glaukos Corporation

Market Cap 10.88B 9.4B 8.83B 8.03B 15.1B 1,040B 15.35B 103B 40.45B 521B 40.85B 39.96B 1,731B P/E 2026 *
-228x
P/E 2027 * 628x
Enterprise Value 10.7B 9.25B 8.69B 7.9B 14.85B 1,024B 15.1B 102B 39.8B 513B 40.19B 39.32B 1,703B EV / Sales 2026 *
15.5x
EV / Sales 2027 * 12.6x
Free-Float
96.35%
Yield 2026 *
-
Yield 2027 * -
1 day-2.60%
1 week+2.51%
Current month+10.68%
1 month+17.65%
3 months+28.14%
6 months+68.57%
Current year+63.43%
1 week 177.56
Extreme 177.565
190
1 month 145.78
Extreme 145.7759
190
Current year 93.96
Extreme 93.96
190
1 year 73.16
Extreme 73.16
190
3 years 59.22
Extreme 59.22
190
5 years 33.33
Extreme 33.33
190
10 years 23.08
Extreme 23.075
190
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap.
11/08/26 Fiscal year

Chairperson

180,000 0.3139%
07/08/26 Fiscal year

Chief Financial Officer

60,000 0.1046%
31/07/26 Sell

Director

-525 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-2.60%+2.51%+105.35%+145.94% 10.88B
-0.55%+0.05%-11.18%+19.08% 130B
-0.86%-1.53%-18.54%+1.53% 12.49B
-2.43%-4.22%-44.57%-67.31% 4.51B
-0.88%+0.67%-24.25%+42.79% 2.72B
-1.32%-1.42%-21.31%-14.54% 1.66B
-0.17%-0.04%-33.47%-35.59% 1.66B
-1.89%-5.09%-34.94%-76.83% 1.65B
+1.56%-2.07%-11.81%-53.68% 1.5B
Average -1.02%-0.93%-10.53%-4.29% 18.58B
Weighted average by Cap. -0.76%-0.07%-5.82%+21.60%

Financials

2026 *2027 *
Net sales 691M 597M 561M 510M 959M 66.06B 975M 6.57B 2.57B 33.08B 2.59B 2.54B 110B 845M 729M 685M 623M 1.17B 80.76B 1.19B 8.03B 3.14B 40.44B 3.17B 3.1B 134B
Net income -51.88M -44.81M -42.11M -38.3M -72M -4.96B -73.19M -493M -193M -2.48B -195M -191M -8.26B 18.93M 16.35M 15.36M 13.97M 26.26M 1.81B 26.7M 180M 70.37M 906M 71.06M 69.52M 3.01B
Net Debt -175M -151M -142M -129M -243M -16.72B -247M -1.66B -650M -8.37B -657M -642M -27.83B -273M -236M -221M -201M -379M -26.09B -385M -2.59B -1.01B -13.06B -1.02B -1B -43.42B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
14/08/26 US$184.53 -2.60% 743,405
13/08/26 US$189.45 +1.51% 762,150
12/08/26 US$186.63 +2.54% 754,151
11/08/26 US$182.00 +0.32% 723,323
10/08/26 US$181.42 +0.78% 646,071
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
184.53USD
Average target price
196.46USD
Spread / Average Target
+6.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock